88 results about "Receptor type" patented technology

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions that respond favorably to PTPN1 or PTPN2 inhibitor treatment, such as cancer or metabolic diseases.

Provided herein are degrader compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 degrader treatment, e.g., a cancer or a metabolic disease.

Provided herein are methods using a combination comprising a protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and an additional therapeutic agent for treating diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

This application relates generally to the field of Bone Morphogenetic Protein (BMP) antagonists (soluble ALK6 fusion proteins), compositions thereof, and methods for use in treating neurodegenerative diseases and / or demyelinating diseases.

The invention provides a preparation method and application of a donor-receptor type two-dimensional imino CTF photocatalyst, and belongs to the technical field of photocatalyst preparation.The preparation method of the CTF photocatalyst comprises the following steps that 2, 4, 6-tris (4-aminophenyl)-1, 3, 5-triazine, terephthalaldehyde and 2, 4, 6-tris (4-aminophenyl)-1, 3, 5-triazine are mixed according to a certain proportion, and the donor-receptor type two-dimensional imino CTF photocatalyst is obtained. The preparation method comprises the following steps: by taking 2, 5-dimethoxy terephthalaldehyde or 2, 5-dihydroxy terephthalaldehyde as a raw material, reacting in a mixed solution of mesitylene / dioxane / acetic acid in a certain proportion for 3 days by adopting an inert gas sealing-solvothermal method, centrifuging the obtained product, sequentially washing with tetrahydrofuran and acetone for multiple times, and carrying out vacuum drying, thereby obtaining the 2, 5-dimethoxy terephthalaldehyde / 2, 5-dihydroxy terephthalaldehyde. The two-dimensional triazine CTF photocatalysts with different donor-receptor types are obtained. The preparation method comprises the following steps: by taking acetonitrile as a solvent, dispersing a photocatalyst into an arylamine solution with a certain concentration, stirring for 0.5 hour in a dark place, and carrying out catalytic reaction under visible light (lambda is greater than or equal to 420 nm), so that the preparation of the high-efficiency catalytic arylamine oxidative coupling reaction under the visible light is realized.

Provided herein are compounds, compositions, and methods that are useful for inhibiting protein tyrosine phosphatases, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and that are useful for treating related diseases, disorders, or conditions, such as cancer or metabolic diseases, that respond favorably to treatment with a PTPN1 or PTPN2 inhibitor.

Provided is an anti-PD-L1 antibody which has excellent activity in blocking the interaction between PD-1 and PD-L1. A multifunctional molecule comprising the anti-PD-L1 antibody or fragment thereof fused to an extracellular structure of human TGF-beta receptor type 2 is also provided.

Provided is an anti-PD-L1 antibody which has excellent activity in blocking the interaction between PD-1 and PD-L1. A multifunctional molecule comprising the anti-PD-L1 antibody or fragment thereof fused to an extracellular structure of human TGF-beta receptor type 2 is also provided.

The invention belongs to the field of porous organic materials, and particularly relates to a hydrogen bond organic framework material based on electron donor-receptor type organic elements and a preparation method and application thereof. The hydrogen bond organic framework material comprises a plurality of electron donor-acceptor type organic elements, the electron donor-acceptor type organic elements are constructed through the synergistic effect of pi-pi interaction force, and an electron donor-acceptor type organic element monomer comprises an electron donor and an electron acceptor connected to the electron donor. The hydrogen bond organic framework material provided by the invention has excellent chemical and thermal stability by utilizing the synergistic effect of multiple hydrogen bonds between electron donor-receptor type organic elements and pi-pi interaction force, and can preserve permanent pore channels.

The MYC and NMYC transcription factors (TFs) play a key role in cell proliferation and are overexpressed in most cancer cells. However, in normal cells their overexpression triggers safeguard mechanisms promoting cell death and cellular senescence, which are bypassed in cancer cells. Here, the inventors reveal that in normal cells MYC binds to the Inositol 1,4,5-Trisphosphate Receptor type 1 (ITPR1) gene and upregulates its expression, triggering an ER-mitochondria calcium (Ca2+) transfer, which is involved in MYC-induced cell death and senescence. Supporting a tumor suppressive role of MYC / ITPR1 axis, ITPR1 expression is generally decreased in cancer and reactivation of this pathway induces cancer cell death. Nevertheless, some cancer cells, generally expressing high levels of MYCN and / or MYC, also express high level of ITPR1, which correlates with high expression of BCL2, encoding an inhibitor of ITPR1. Strikingly, in high-risk MYCN-amplified neuroblastoma, ITPR1 expression is controlled by NMYC and its level correlates with worse patient survival. In these cells, blocking the interaction between BCL2 and ITPR1, via an BCL2-BH4 domain inhibitor induces mitochondrial Ca2+ accumulation and cell death, and decreases tumor size. Thus, the present invention relates to a method for treating MYChigh cancer, and in particular NMYC--amplified neuroblastoma in a subject by administering an BCL2-BH4 domain inhibitor.

The present invention relates to a separated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen binding domain, and the extracellular antigen binding domain comprises an antibody or antibody fragment that binds to a human CXC chemokine receptor type 5 (CXCR5) protein. The present invention further relates to nucleic acid molecules encoding the CAR of the present invention, genetically modified immune cells expressing the CAR of the present invention, preferably T cells, and the use of the cells in the treatment of medical conditions related to the presence of pathogenic cells expressing CXCR5, wherein the pathogenic cells expressing CXCR5 are preferably pathogenic mature B cells and / or memory B cells and / or pathogenic T cells and / or follicular helper T cells, particularly mature B cell non-Hodgkin lymphoma (B-NHL), T cell non-Hodgkin lymphoma, or autoantibody-dependent autoimmune diseases, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.

Compositions and methods for editing, e.g., altering a DNA sequence, within a TGFβR2 are provided. Compositions and methods for reducing or eliminating TGFβR2 protein expression in a cell are provided. Compositions and methods for immunotherapy are provided.

The invention relates to the technical field of electrochemical luminescence, and discloses an electrochemical luminescence array sensor as well as a preparation method and application thereof. The electrochemical luminescence array sensor comprises a plurality of working electrodes; the surface of each working electrode is sequentially modified by a donor-receptor type covalent organic framework material and cyclodextrin, and the cyclodextrin for modifying each working electrode is different from each other; the number of the number is not less than 5. A donor-acceptor structure of the covalent organic framework material can directionally transmit electrons, and compared with a traditional electrochemical luminescent material, the luminescent efficiency is remarkably improved; the material has the advantages of ordered structure, high crystallinity and good thermal stability, has a rigid covalent bond network and a regular pore channel structure, and is good in stability and strong in anti-interference capability; a plurality of cyclodextrins are respectively modified on the surface of an electrode, a multi-mode chiral recognition interface is constructed, and the bottleneck of insufficient selectivity of a single chiral sensor is broken through; the array sensor has the advantages of being rapid, sensitive, non-destructive, intelligent and the like.

The present invention relates to compounds and methods useful for dual inhibition of C-X-C receptor type 4 (CXCR4) and Bruton's tyrosine kinase (BTK). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Compositions and methods for editing, e.g., altering, DNA sequences within TGFβR2 are provided. Compositions and methods for reducing or eliminating TGFβR2 protein expression in a cell are provided. Compositions and methods for immunotherapy are provided.

A method of identifying oxidative stress caused by ageing and / or ultraviolet (UV) light exposure in a test cell. The method includes determining the methylation status of at least one CpG site in Protein Tyrosine Phosphatase Receptor Type N2 (PTPRN2), and / or the regulatory region of PTPRN2 in a DNA sample obtained from the test cell, and comparing the methylation status of the CpG site of PTPRN2 with that of a control without oxidative stress caused by ageing and / or UV light exposure. A difference in the methylation status of the CpG site of PTPRN2, and / or the regulatory region of PTPRN2 in the test cell compared to the CpG site in the control is indicative of the test cell having oxidative stress caused by exposure of the cell to UV light and / or ageing.

The present invention relates to antisense oligonucleotides (ASO) for use in treating, preventing, or ameliorating the progression of conditions such as type 2 diabetes mellitus (T2DM) and insulin resistance, leptin resistance, and obesity, Rater Syndrome, and cancer. Specifically, a thiomorpholino-containing ASO targets a protein tyrosine phosphatase non-receptor type 1 (PTPN1) gene transcript and induces exon skipping (including exon 2) of the transcript during RNA processing, thereby inhibiting expression of the protein tyrosine phosphatase-1B (PTP1B) protein.

Provided in the present invention are an siRNA for inhibiting the expression of the activin A receptor type 1C (ACVR1C) gene, and a conjugate thereof. The siRNA comprises a sense strand and an antisense strand. The antisense strand comprises at least 17 consecutive nucleotides that differ from nucleotide sequences set forth in SEQ ID NO: 1236-SEQ ID NO: 2470 by no more than 4 nucleotides. The antisense strand is 17-30 nucleotides in length; and the sense strand is 17-30 nucleotides in length, and is at least partially or completely complementary to the antisense strand. The siRNA, siRNA conjugate and pharmaceutical composition provided in the present invention exhibit good stability, great ACVR1C gene inhibitory activity, and satisfactory cytotoxicity and immunostimulatory activity.

Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3 / 14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

Polypeptides having the amino acid of one of SEQ ID NO: 1-9 are provided that bind to convex protein target sites on transformimg growth factor beta receptor type 2 (TGFbRII), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), or programmed death-ligand 1 (PD-L1), and methods for their use in treating cancer or tissue fibrosis.

The present disclosure provides methods and compositions for reducing the addictive liability of opioid analgesics in a subject, for example, by co-administering to the subject the opioid and a serotonin receptor type 2 (5HT2) agonist or a serotonin (5HT) releasing agent. The disclosed methods include methods for preventing opioid abuse, methods for reducing the rewarding effect of an opioid, methods for reducing the addictive liability of an opioid, methods for eliminating or substantially reducing the tendency for a subject to develop physical dependence, tolerance, and / or withdrawal symptoms with respect to an opioid, and methods for eliminating or substantially reducing the tendency for a subject to use opioids in ways not prescribed, take opioids more often or in larger amounts than prescribed, and / or use opioids recreationally. The methods can be performed on a subject, such as a patient (e.g., a human patient).

Provided herein are useful for degrading protein tyrosine phosphatase, such as protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and useful for treating related diseases, disorders and conditions that contribute to the treatment of PTPN1 or PTPN2 degrading agents, degradation agent compounds, compositions, and methods for treating cancer, such as cancer or metabolic diseases.

Small molecule CXC chemokine receptor type 4 (CXCR4) agonists are disclosed, methods of their manufacture, and uses thereof, in particular to improve healing and reduce the risk of injury for wound healing in diabetes.

Provided herein are methods and compositions for inhibiting the growth of a cancer cell or treating a cancer, wherein the cancer cell or cancer expresses a mutant protein tyrosine phosphatase receptor type F (PTPRF) or a mutant protein tyrosine phosphatase receptor type D (PTPRD) protein.

The invention provides an inhibitor for use in treating KRAS-mutant cancers, uses, and methods for treating KRAS-mutant cancers, methods for selecting subjects predicted to respond therapeutically to a treatment comprising the inhibitor. The invention also provides kits.

Provided herein are methods of using a combination comprising protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1) and an additional therapeutic agent to treat a disease (e.g., cancer or metabolic disease) that produces an advantageous response to PTPN1 or PTPN2 inhibitor treatment.

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor (CAR) T cells having reduced levels of an interleukin (IL) 4 polypeptide, having reduced levels of a transcription factor 7 (TCF7) polypeptide, having reduced levels of a protein tyrosine phosphatase non-receptor type 2 (PTPN2) polypeptide, and / or having reduced levels of a protein tyrosine phosphatase non-receptor type 3 (PTPN3) polypeptide are provided. Methods and materials for using such CAR T cells in an adoptive cell therapy (e.g., a CAR T cell therapy) to treat a mammal (e.g., a human) having cancer also are provided

A chip containing type bone implant capable of achieving negative pressure drainage comprises a support shell and a base, and an inner cavity of the support shell is filled with filler materials. The support shell and the base are detachably connected, and the internal filler can be placed in an internal cavity of the support shell through the tail end opening. A fluid suction assembly is arranged on the base; a positioning insertion piece is arranged at the head end of the base, and the positioning installation piece of the support shell and the positioning insertion piece at the head end of the base are in surface fit connection; a sealed annular space is formed at the head end position of the positioning installation piece and the positioning insertion piece, and abrasion particles generated when the positioning installation piece and the positioning insertion piece are used in cooperation are collected in the sealed annular space. The novel implant is applied, in the process of treating femoral head necrosis, the internal pressure of the femoral head can be reduced, an intraosseous circulation environment can be established, and non-degradable material particles can be prevented from invading the human body.

The invention discloses a donor-receptor type carbon nitride photocatalyst as well as a preparation method and application thereof, and the preparation method of the donor-receptor type carbon nitride photocatalyst comprises the following steps: S1, preparing an amino-containing carbon nitride nanosheet; s2, the carbon nitride nanosheet and an aggregation-induced emission unit are subjected to a Schiff base reaction in a solvent, and the donor-acceptor type carbon nitride photocatalyst is obtained, the aggregation-induced emission unit in the step S2 is one or more of a triphenylamine derivative and a tetraphenyl ethylene derivative. The organic molecules with aggregation-induced emission characteristics are covalently modified, the conjugated structure of the organic molecules is adjusted, and the electron donating capability is regulated, so that the light absorption capability and the intramolecular charge transfer capability of the donor-acceptor type carbon nitride photocatalyst can be effectively improved, and the photocatalytic hydrogen production performance is remarkably improved.